Buy para-Methoxymethamphetamine (4-methoxy-N) Cas 22331-70-0
para-Methoxymethamphetamine (PMMA), also known as 4-methoxy-N-methylamphetamine (4-MMA), is a serotonergic drug of the amphetamine family related to para-methoxyamphetamine (PMA).[1][3] It is the 4-methoxy analogue of methamphetamine.[1][3]
Little is known about the pharmacological properties, metabolism, and toxicity of PMMA; because of its structural similarity to PMA, which has known toxicity in humans, it is thought to have considerable potential to cause harmful side effects or death in overdose.[4] In the early 2010s, a number of deaths in users of the drug MDMA were linked to misrepresented tablets and capsules of PMMA.[5]
PMMA is a serotonin–norepinephrine releasing agent (SNRA)[6][7][8][9] as well as potent monoamine oxidase inhibitor (MAOI).[10] It has a reduced tendency to produce severe hyperthermia at low doses compared to PMA,[11][12] but at higher doses, side effects and risk of death become similar to those of PMA.[13]
The synthesis and effects of PMMA were described by American experimental chemist Alexander Shulgin in his book PiHKAL, where it is referred to by the name “methyl-MA”, as the N-methylated form of 4-MA (PMA).[1]
Use and effects
According to Alexander Shulgin in his book PiHKAL (Phenethylamines I Have Known and Loved), the effects of PMMA at a dose of 110 mg orally included tachycardia, compulsive yawning, and nystagmus, among others.[1] It was said to have some of the physical side effects of the entactogen MDMA but none of its central effects.[1] No psychedelic-like effects were mentioned.[1]
Pharmacology
Pharmacodynamics
PMMA is a monoamine releasing agent (MRA).[6][7][8][9] The drug’s EC50Tooltip half-maximal effective concentration values for induction of monoamine release in rat brain synaptosomes have been reported for the individual enantiomers of PMMA.[6][7][8] In the case of (S)-PMMA, they were 41 nM for serotonin, 147 nM for norepinephrine, and 1,000 nM for dopamine, whereas for (R)-PMMA, they were 134 nM for serotonin, >14,000 nM for norepinephrine, and 1,600 nM for dopamine.[6][7][8] Hence, PMMA appears to be a serotonin–norepinephrine releasing agent (SNRA) with weak effects on dopamine release.[6][7][8][9] The drug has been found to strongly release serotonin and to weakly release dopamine in the brain in rodents
Reviews
There are no reviews yet.